Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL
NCT07226752Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Genmab. Started Oct 2022; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07226752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226752.